Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rehabilitation Coordinators in Specialist Psychiatry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03729050
Recruitment Status : Recruiting
First Posted : November 2, 2018
Last Update Posted : June 30, 2020
Sponsor:
Information provided by (Responsible Party):
Ingrid Anderzen, Uppsala University

Brief Summary:
REKO-A is a randomized controlled intervention study that addressed women and men on sick leave in Uppsala County. Participants which are on sick leave due to mental illness.

Condition or disease Intervention/treatment Phase
Mental Disorder Rehabilitation Behavioral: Rehabilitation Coordinator in Specialist Psychiatry Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Rehabilitation Coordinators in Specialist Psychiatry
Actual Study Start Date : October 24, 2018
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention with rehabilitation coordinator Behavioral: Rehabilitation Coordinator in Specialist Psychiatry
Rehabilitation Coordinator service in Specialist Psychiatry

No Intervention: Control



Primary Outcome Measures :
  1. Return to work (RTW)/entry into work or studies [ Time Frame: 1 year ]
    Number of Participants that have RTW/entry into work or studies

  2. Magnitude of sick leave [ Time Frame: 1 year ]
    Proportion of sick leave in the study population

  3. Length of sick leave [ Time Frame: 1 year ]
    Sick leave duration



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be on sick leave
  • Have moderate to severe affective and / or moderate / severe anxiety disorder, such as: Bipolar disorder, depression, posttraumatic stress disorder, generalized anxiety disorder, neuropsychiatric disability
  • Enrolled at the Academic hospital in Uppsala

Exclusion Criteria:

  • High suicidal risk
  • Extensive somatic disorders (somatic multichannel)
  • Patients outside Uppsala County
  • Taking part in an ongoing vocational rehabilitation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03729050


Locations
Layout table for location information
Sweden
Uppsala university Recruiting
Uppsala, Sweden, SE-75122
Contact: Åsa Andersén, PHD    00184716575    asa.andersen@pubcare.uu.se   
Principal Investigator: Ingrid Anderzén, PHD         
Sponsors and Collaborators
Uppsala University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ingrid Anderzen, Associate professor, Uppsala University
ClinicalTrials.gov Identifier: NCT03729050    
Other Study ID Numbers: REKO-A
First Posted: November 2, 2018    Key Record Dates
Last Update Posted: June 30, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ingrid Anderzen, Uppsala University:
Mental Disorder
Rehabilitation
Additional relevant MeSH terms:
Layout table for MeSH terms
Mental Disorders
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders